Inflammation is the body’s natural defense mechanism. But when it becomes chronic, runaway, or misdirected against the body’s own tissues, it becomes the root of some of the most debilitating diseases known to modern medicine. A reliable, effective and well-tolerated corticosteroid is essential to clinical practice in a variety of specialties including autoimmune conditions, allergic disorders, muscular dystrophies and nephrotic syndrome.

DEFRACKET 6 from Steris Healthcare containing Active Pharmaceutical Ingredient Deflazacort 6 mg, matches this clinical need perfectly. Deflazacort is an oxazoline derivative of prednisolone and a newer generation corticosteroid developed to provide the potent anti-inflammatory and immunosuppressive effects of conventional steroids with a substantially improved metabolic safety profile. Deflazacort 6 mg is An oral corticosteroid medicine used to reduce inflammation and regulate overactive immune system responses.

Why Deflazacort 6 mg Is Important in Modern Anti-Inflammatory and Immunosuppressive Therapy

Corticosteroids have been a cornerstone of medicine since the 1950s, but their long-term use has always been complicated by a well-documented adverse effect burden — weight gain, hyperglycemia, bone density loss, fluid retention, and growth suppression in children. For decades, clinicians faced a difficult choice: tolerate the disease or tolerate the drug's consequences.

Deflazacort 6 mg, available as DEFRACKET 6 from Steris Healthcare, was developed specifically to shift that equation. As a newer-generation corticosteroid, it retains the full anti-inflammatory and immunosuppressive potency needed to manage serious inflammatory conditions while demonstrating a comparatively reduced impact on glucose metabolism, body weight, and bone mineral density when used at equivalent therapeutic doses compared to prednisolone or prednisone.

This distinction is not merely pharmacological — it is deeply practical. For a child with Duchenne Muscular Dystrophy who will require corticosteroid therapy for years, or an adult with a chronic autoimmune condition managed over decades, the difference in metabolic side effect profile translates directly into better quality of life, higher long-term adherence, and fewer steroid-related complications requiring additional medical management.

Steris Healthcare's decision to offer DEFRACKET 6 at the widely used 6 mg tablet strength gives prescribers the precise dose flexibility needed to individualize therapy across pediatric and adult populations — a critical feature in a molecule where weight-based dosing is standard practice, particularly in DMD management.

Mechanism of Action: How Deflazacort 6 mg Works Inside the Body

Understanding how Deflazacort 6 mg works helps explain both its therapeutic breadth and its side effect profile. Like all corticosteroids, Deflazacort is a steroid hormone that exerts its effects primarily at the level of gene transcription — it works by entering cells and binding to intracellular glucocorticoid receptors in the cytoplasm.

Once bound, the Deflazacort-receptor complex translocates into the cell nucleus, where it interacts with specific DNA sequences called glucocorticoid response elements (GREs). This interaction either activates or suppresses the transcription of a wide range of inflammatory and immune-regulatory genes. The net result is a profound and broad suppression of the inflammatory cascade — reducing the production of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and prostaglandins, while simultaneously inhibiting the migration and activation of immune cells including lymphocytes, macrophages, neutrophils, and eosinophils.

Deflazacort is actually a prodrug — it is rapidly converted after oral absorption to its active metabolite, 21-desacetyl-deflazacort, which is responsible for virtually all of its pharmacological activity. This biotransformation occurs primarily in the gastrointestinal mucosa and liver. The active metabolite has a plasma half-life of approximately 1.1 to 1.9 hours, with peak plasma concentrations typically reached within 1.5 to 2 hours after oral administration.

What distinguishes Deflazacort from prednisolone at the receptor level is a subtly different binding profile that results in comparatively less stimulation of receptors involved in glucose and fat metabolism while maintaining full anti-inflammatory potency — the molecular basis for its improved metabolic tolerability. In terms of anti-inflammatory potency, 6 mg of Deflazacort is considered approximately equivalent to 5 mg of prednisolone.

What Are the Benefits of Deflazacort 6 mg?

DEFRACKET 6 by Steris Healthcare offers a distinctive combination of therapeutic efficacy and comparative safety advantages that set it apart from older corticosteroids:

• Potent Anti-Inflammatory Action: Deflazacort 6 mg delivers robust suppression of the full inflammatory cascade — cytokines, prostaglandins, and immune cell activation — making it effective across a wide range of inflammatory conditions.
• Improved Metabolic Profile: Compared to prednisolone at equivalent anti-inflammatory doses, Deflazacort demonstrates less propensity for weight gain, hyperglycemia, and dyslipidemia — a clinically significant advantage for long-term therapy.
• Relative Bone Sparing: Clinical evidence suggests Deflazacort 6 mg has a comparatively lower impact on bone mineral density than equivalent doses of prednisolone, though bone health monitoring remains important with any long-term corticosteroid use.
• Lower Weight Gain Tendency: Particularly important in pediatric patients and individuals with Duchenne Muscular Dystrophy, where weight management is both medically and functionally critical.
• Broad Therapeutic Versatility: Indicated across rheumatology, pulmonology, nephrology, neurology, dermatology, and allergy — giving prescribers a single molecule applicable across multiple specialties.
• Precise Dose Flexibility: The 6 mg tablet strength of DEFRACKET 6 allows accurate weight-based dosing — essential in pediatric practice and in conditions like DMD where precise milligram-per-kilogram dosing is standard.
• FDA-Validated in DMD: Deflazacort holds the distinction of being FDA-approved specifically for Duchenne Muscular Dystrophy — a landmark validation of its efficacy in one of the most challenging pediatric neuromuscular conditions.
• Manufactured by Steris Healthcare: DEFRACKET 6 is produced under stringent GMP standards, ensuring consistent potency, purity, and tablet integrity across every batch.

Indications, Efficacy, and Clinical Evidence for Deflazacort 6 mg

DEFRACKET 6 (Deflazacort 6 mg) by Steris Healthcare is indicated for use across a broad and clinically significant range of conditions where anti-inflammatory or immunosuppressive therapy is required.

Primary clinical indications include:

• Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and above
• Rheumatoid arthritis and juvenile idiopathic arthritis
• Systemic lupus erythematosus (SLE)
• Nephrotic syndrome and glomerulonephritis
• Bronchial asthma (acute exacerbations and chronic severe forms)
• Allergic disorders including severe allergic rhinitis and urticaria
• Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
• Polymyalgia rheumatica and other connective tissue diseases
• Dermatological conditions including severe eczema, pemphigus, and psoriasis
• Organ transplant rejection prophylaxis (as part of immunosuppressive regimens)
• Inflammatory eye conditions (uveitis, scleritis)

Clinical Evidence Supporting Deflazacort 6 mg

The evidence base for Deflazacort 6 mg is extensive and spans multiple therapeutic areas:

1. Duchenne Muscular Dystrophy: The pivotal randomized controlled trial comparing deflazacort with placebo and prednisone in DMD patients demonstrated that deflazacort-treated patients maintained significantly better muscle strength and function over 12 months. Deflazacort-treated patients showed less weight gain compared to prednisone-treated patients — a critical finding given the functional implications of obesity in this population. This data formed the basis of FDA approval in 2017.
2. Long-term DMD outcomes: Long-term observational data spanning up to 10 years in DMD cohorts showed that deflazacort significantly delayed the loss of ambulation (the ability to walk independently), improved respiratory function, and reduced the rate of scoliosis development compared to untreated patients.
3. Nephrotic Syndrome: Multiple randomized trials in pediatric and adult nephrotic syndrome demonstrate that Deflazacort produces remission rates comparable to prednisolone while causing significantly less weight gain and cushingoid features — particularly important in a population of children who already face psychosocial challenges from their disease.
4. Rheumatoid Arthritis: Head-to-head comparative studies have demonstrated equivalent disease-modifying activity for Deflazacort versus prednisolone in rheumatoid arthritis, with a statistically significant reduction in steroid-related adverse metabolic effects including glucose intolerance in the Deflazacort arm.
5. Asthma and Allergic Conditions: Deflazacort has demonstrated rapid clinical efficacy in acute severe asthma exacerbations, with systemic bioavailability comparable to prednisolone and a favorable short-term tolerability profile for acute use.

For patients and caregivers researching Deflazacort 6 mg options in India, the clinical evidence strongly supports investing in a quality-manufactured formulation. DEFRACKET 6 by Steris Healthcare ensures that this internationally validated molecule is delivered with the manufacturing precision it demands.

Side Effects of DEFRACKET 6 (Deflazacort 6 mg)

Deflazacort 6 mg, like all corticosteroids, carries an adverse effect profile that is closely related to dose and duration of use. Most side effects observed with short-term use at therapeutic doses are mild and reversible. Long-term or high-dose use requires careful clinical monitoring.

Commonly reported side effects include:

• Weight gain — Present but comparatively less pronounced than with prednisolone or prednisone at equivalent doses; dietary management is still advisable.
• Increased appetite — Particularly noted during initial weeks of treatment.
• Mood changes — Including mild euphoria, anxiety, or emotional lability; more significant mood disturbances are possible at higher doses.
• Insomnia — Sleep disruption, especially if the dose is taken late in the day; morning dosing is recommended to minimize this.
• Facial puffiness (cushingoid features) — Moon face and mild fluid retention with long-term use.
• Acne and skin thinning — Particularly with prolonged treatment courses.
• Increased susceptibility to infections — Immune suppression reduces the body's ability to fight bacterial, viral, and fungal infections.
• Gastrointestinal discomfort — Nausea, dyspepsia, or mild abdominal discomfort; taking with food substantially reduces GI irritation.
• Elevated blood glucose — Less pronounced than with prednisolone but still clinically relevant, especially in pre-diabetic or diabetic patients.

Serious Side Effects of Deflazacort 6 mg

The following require immediate medical evaluation:

• Adrenal insufficiency and HPA axis suppression — Prolonged use suppresses the hypothalamic-pituitary-adrenal (HPA) axis. Abrupt withdrawal after long-term use can trigger acute adrenal crisis — a life-threatening emergency characterized by severe hypotension, vomiting, and collapse.
• Severe osteoporosis and pathological fractures — Long-term corticosteroid use, even with Deflazacort's relative bone-sparing advantage, can significantly reduce bone mineral density. Vertebral and hip fractures represent serious risks in elderly patients.
• Avascular necrosis of bone — Particularly of the femoral head; a rare but severely debilitating complication of long-term steroid use.
• Serious infections — Including tuberculosis reactivation, invasive fungal infections, and opportunistic bacterial infections. Patients should be screened for latent TB before initiating long-term therapy.
• Posterior subcapsular cataracts and glaucoma — Both are recognized complications of prolonged corticosteroid use requiring regular ophthalmological monitoring.
• Growth retardation in children — Long-term steroid use can impair linear growth in pediatric patients; regular height and weight monitoring is essential.
• Psychiatric disturbances — Steroid-induced psychosis, severe depression, or mania can occur, particularly at high doses or in predisposed individuals.
• Hypertension and cardiovascular effects — Fluid retention and sodium retention can elevate blood pressure, increasing cardiovascular risk during long-term therapy.

Available Substitutes for DEFRACKET 6 (Deflazacort 6 mg)

The following brands contain Deflazacort 6 mg as the active ingredient and may be considered as therapeutic substitutes under direct medical supervision:

• Moaid 6 mg (Sun Pharma) — A widely prescribed branded Deflazacort formulation from a major Indian manufacturer.
• Defcort 6 mg (Macleods Pharmaceuticals) — One of the most recognized Deflazacort brands in Indian clinical practice.
• Decortil 6 mg — Available through select pharmacy channels across India.
• Deflazacort 6 mg generic formulations — Various DCGI-approved generic versions are available; quality can vary between manufacturers.
• DEFRACKET 6 (Steris Healthcare) — The brand reviewed in this article, offering GMP-manufactured Deflazacort 6 mg with consistent quality and accessible pricing.

Any brand substitution should occur only under prescribing physician supervision. Although the active ingredient and dose are identical, excipient differences in tablet formulation may affect dissolution and clinical performance.

Dosage Guidelines for DEFRACKET 6 (Deflazacort 6 mg) by Steris Healthcare

Deflazacort 6 mg dosing is highly individualized and depends on the specific indication, disease severity, patient age, body weight, and clinical response. The following guidelines reflect established prescribing standards.

Duchenne Muscular Dystrophy (the most precisely defined dosing indication):

• Recommended dose: 0.9 mg/kg/day orally, once daily
• The 6 mg tablet strength of DEFRACKET 6 allows accurate weight-based dose calculation across the pediatric weight range
• Administer once daily in the morning with food

General inflammatory and autoimmune conditions (adult dosing):

• Initial dose: 6 mg to 36 mg per day (1 to 6 tablets of DEFRACKET 6), depending on severity
• Maintenance dose: Titrated down to the lowest effective dose that maintains disease control — typically 6 mg to 18 mg/day for chronic conditions
• Once daily morning dosing is preferred to minimize HPA axis suppression

Pediatric dosing (non-DMD conditions):

• Starting dose: 0.25 mg/kg to 1.0 mg/kg/day, individualized by condition and severity
• Administer as a single morning dose or in divided doses for higher-dose regimens

Tapering protocol:

• Never stop Deflazacort 6 mg abruptly after more than 2–3 weeks of continuous use
• Dose must be tapered gradually — typically reducing by 1–2 mg every 1–2 weeks — to allow the adrenal glands to resume normal cortisol production
• The rate of tapering should be guided by clinical response and adrenal function

Administration: Always take DEFRACKET 6 with food to reduce gastrointestinal irritation and enhance tolerability. Morning administration is strongly preferred to align with the body's natural cortisol rhythm and reduce sleep disturbance.

Precautions & Warnings: Important Information Before Using DEFRACKET 6 (Deflazacort 6 mg)

• Never stop abruptly: After more than two to three weeks of use, DEFRACKET 6 must always be tapered gradually under medical supervision. Sudden discontinuation risks acute adrenal insufficiency — a potentially fatal complication.
• Infection risk: Deflazacort 6 mg suppresses immune function. Patients must avoid close contact with individuals who have active infections, particularly chickenpox or measles, which can cause severe or fatal illness in immunosuppressed individuals.
• Tuberculosis screening: All patients being considered for long-term Deflazacort therapy should be screened for latent or active tuberculosis before initiating treatment.
• Vaccination caution: Live vaccines (including MMR, varicella, yellow fever) are contraindicated during significant immunosuppressive therapy. Discuss your vaccination status with your doctor before starting.
• Diabetes and blood sugar monitoring: Even though Deflazacort has a comparatively lower hyperglycemic effect than prednisolone, regular blood glucose monitoring is essential — particularly in patients with pre-existing diabetes or those at risk.
• Bone health protection: Long-term therapy requires calcium and vitamin D supplementation and, in high-risk individuals, baseline and periodic bone density (DEXA) scanning. Bisphosphonate therapy may be considered for high-risk patients.
• Gastrointestinal protection: Patients taking Deflazacort 6 mg concomitantly with NSAIDs or aspirin have an elevated risk of peptic ulceration. Proton pump inhibitor (PPI) co-administration is often recommended.
• Growth monitoring in children: Regular height and weight monitoring is mandatory for all pediatric patients on long-term Deflazacort therapy.
• Eye examinations: Annual ophthalmological review for cataracts and intraocular pressure is advisable for patients on long-term DEFRACKET 6 therapy.
• Pregnancy and breastfeeding: Use only when clearly necessary; discuss all risks and benefits with your physician. Deflazacort crosses the placenta and may be present in breast milk.
• Drug interactions: Deflazacort interacts with rifampicin (reduces steroid levels), phenytoin, carbamazepine, ketoconazole, cyclosporine, NSAIDs, anticoagulants, and diuretics. Always provide your complete medication list to your prescriber.
• Stress dosing: Patients on long-term Deflazacort 6 mg may need supplemental steroid doses during physiological stress (surgery, serious illness, major trauma) — discuss a stress dosing plan with your physician.

Conclusion

DEFRACKET 6 — containing Deflazacort 6 mg and manufactured by Steris Healthcare — is a clinically sophisticated, internationally validated corticosteroid that occupies a uniquely important position in modern anti-inflammatory and immunosuppressive therapeutics. Its proven efficacy across a wide spectrum of conditions — from Duchenne Muscular Dystrophy and nephrotic syndrome to rheumatoid arthritis, severe asthma, and systemic autoimmune disorders — combined with its meaningfully improved metabolic tolerability compared to prednisolone, makes it a compelling choice for both short-term and long-term management scenarios.

The availability of DEFRACKET 6 at the precise 6 mg tablet strength through Steris Healthcare gives Indian clinicians and patients access to this globally trusted molecule with the assurance of GMP-standard manufacturing, consistent potency, and dose accuracy that complex conditions demand. For patients and caregivers navigating the landscape of Deflazacort 6 mg options in India, DEFRACKET 6 by Steris Healthcare represents a quality-assured, clinically supported, and practically accessible solution. As always, all decisions regarding initiation, dose adjustment, and duration of corticosteroid therapy must be made in close partnership with your prescribing physician — because the power of Deflazacort 6 mg is best realized when guided by clinical expertise and individualized care.

Frequently Asked Questions

Q1. What is Deflazacort 6 mg used for?
DEFRACKET 6 (Deflazacort 6 mg) by Steris Healthcare is used to treat a wide range of inflammatory and autoimmune conditions including Duchenne Muscular Dystrophy, rheumatoid arthritis, nephrotic syndrome, severe asthma, systemic lupus erythematosus, inflammatory bowel disease, allergic disorders, and various dermatological and ophthalmic inflammatory conditions.

Q2. How does Deflazacort 6 mg work?
Deflazacort 6 mg is a prodrug converted to its active metabolite after absorption. It works by binding to intracellular glucocorticoid receptors, which then regulate gene transcription to suppress the production of pro-inflammatory cytokines, prostaglandins, and immune cell activity — producing broad anti-inflammatory and immunosuppressive effects throughout the body.

Q3. Is Deflazacort 6 mg better than prednisolone?
At equivalent anti-inflammatory doses (6 mg Deflazacort ≈ 5 mg prednisolone), Deflazacort demonstrates a comparatively lower propensity for weight gain, hyperglycemia, and bone density loss. This metabolic advantage makes it particularly preferred for long-term use and in pediatric patients. Whether it is the right choice for a specific patient depends on their clinical profile and your doctor's judgment.

Q4. What is the dose of Deflazacort 6 mg for Duchenne Muscular Dystrophy?
The recommended dose for DMD is 0.9 mg/kg/day, administered as a single morning oral dose with food. The 6 mg tablet strength of DEFRACKET 6 allows precise weight-based dosing across the pediatric weight range under your neurologist's supervision.

Q5. Can I stop taking Deflazacort 6 mg suddenly?
No. Abrupt discontinuation of Deflazacort 6 mg after more than two to three weeks of use can cause acute adrenal insufficiency — a serious and potentially life-threatening condition. The dose must always be tapered gradually under direct medical supervision.

Q6. What foods should I avoid while taking Deflazacort 6 mg?
Avoid alcohol, which increases gastric irritation and metabolic side effects. Limit high-sodium foods to reduce fluid retention and blood pressure effects. A calcium and vitamin D-rich diet supports bone health during long-term therapy. Your physician may recommend additional dietary guidance based on your specific condition and treatment duration.

Q7. Can Deflazacort 6 mg cause weight gain?
Weight gain is a recognized side effect of Deflazacort, but clinical evidence consistently shows it causes significantly less weight gain than prednisolone or prednisone at equivalent anti-inflammatory doses — a key reason it is preferred in conditions like DMD where weight management is functionally critical.

Q8. Is Deflazacort 6 mg safe for children?
Deflazacort 6 mg is FDA-approved for use in children aged 2 years and above for Duchenne Muscular Dystrophy and is widely used in Indian pediatric practice for other inflammatory conditions. It is considered comparatively safer than older corticosteroids in terms of metabolic effects, but requires careful dose calculation, regular growth monitoring, and close physician supervision in all pediatric patients.

Q9. How long can I take Deflazacort 6 mg?
Duration depends entirely on the underlying condition. For acute conditions, short courses of one to two weeks may suffice. For chronic conditions like DMD or systemic autoimmune disease, long-term therapy — sometimes for years — may be necessary. Long-term use requires regular monitoring of blood glucose, bone density, eye health, blood pressure, and adrenal function.

Product Information

Brand name: DEFRACKET 6 (STERIS HEALTHCARE PVT LTD)

Composition Name: Deflazacort ( 6mg )

Pack size: Strip of 10 tablets

Marketed By: Steris Healthcare Pvt Ltd

Regulatory standard: WHO-GMP certified

Schedule: Valid Prescription Required (prescription only) please create in this manner.